lockFinancial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was KOD. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card
What does Kodiak Sciences (KOD) do?
Kodiak Sciences Inc (KOD) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops antibody-biopolymer drug candidates to treat chronic retinal eye diseases like macular degeneration. Builds biopolymer-conjugated therapies designed to extend how long retinal eye disease treatments remain active inside. It is worth $6.40B on the market.
Market cap
$6.40B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 18, 2026
KOD’s flags, in plain English
Each flag is a number from Kodiak Sciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Stupid Cash
Can pay this year's bills 1.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Insiders Hold
Insiders own 8.6% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Debt Is Driving
Heavy debt, 1166% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
Kodiak Sciences’ market cap is $6.40B: what all of its shares are worth together at today’s price.
What could go wrong with KOD?
The business generates no commercial sales and depends entirely on existing cash reserves to fund late-stage clinical trials. That is one risk on Kodiak Sciences’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Kodiak Sciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. KOD’s filings on SEC.gov. The Margin Monkey is research, not advice.
Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
$144 today for 12 months, then $144/year until you cancel. Cancel anytime, access runs to the end of the paid period. Taxes may apply. No refunds on payments already made. Billing terms.
lockSecure checkout by Stripe. Your card details never reach our servers.
The homework on 1,900+ companies is already done. You make the call.
crownRatings from Strong Buy to Sell
crownPicks, the desk’s short list
Both scores in full
A source on every flag
Statements in plain words
Model portfolios
Alerts on 25 companies
Charts, news and clips
About 39 cents a day on the annual plan.
It is research, not advice: a rating can’t know your situation.
THEMARGINMONKEY
7-day free trial
Read more of KOD.
Your email opens your desk for 7 days. Open KOD and 1 more company in full, the rating included. Each of the other 1,900+ shows up to 5 green flags and 3 red flags.
Members
Sign in.
No password needed. We send a link that signs you in.
It works once and expires in 20 minutes.